Wave Life Sciences Ltd. - Ordinary Shares (WVE) News
Filter WVE News Items
WVE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
WVE News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest WVE News From Around the Web
Below are the latest news stories about WAVE LIFE SCIENCES LTD that investors may wish to consider to help them evaluate WVE as an investment opportunity.
Is Wave Life Sciences Ltd. (WVE) the Best Growth Stock to Buy Now Under $25?We recently compiled a list of the 12 Best Growth Stocks Under $25 to Buy Now. In this article, we are going to take a look at where Wave Life Sciences Ltd. (NASDAQ:WVE) stands against the other growth stocks. AI is the Most Defining Theme of 2025, Says Expert Most experts agree that the AI wave […] |
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in ObesityWVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration WVE-007 is Wave’s first siRNA program to enter clinical development and uses best-in-class oligonucleotide chemistry and GalNAc delivery Wave expects to initiate the first-in-human study of WVE-007 in 1Q 2025 CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Scien |
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET. A live webcast of this presentation can be a |
Wave Life Sciences to Present at Upcoming Investor ConferencesCAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December. 7ᵗʰ Annual Evercore HealthCONx ConferenceDate: Tuesday, December 3, 2024Analyst-led fireside chat: 3:00 p.m. ET Citi 2024 Glob |
Wave Life Sciences to Present at Jefferies London Healthcare ConferenceCAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET. A live webcast of this presenta |
Wave Life Sciences Ltd. (NASDAQ:WVE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$22.20Wave Life Sciences Ltd. ( NASDAQ:WVE ) missed earnings with its latest third-quarter results, disappointing... |
Wave Life Sciences Third Quarter 2024 Earnings: Misses ExpectationsWave Life Sciences ( NASDAQ:WVE ) Third Quarter 2024 Results Key Financial Results Net loss: US$61.8m (down from... |
WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...Despite a net loss, WAVE Life Sciences Ltd (WVE) showcases promising clinical progress and a strengthened financial position to support future growth. |
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue EstimatesWave Life Sciences (WVE) delivered earnings and revenue surprises of -67.86% and 149.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Wave Life Sciences: Q3 Earnings SnapshotSINGAPORE (AP) — Wave Life Sciences Pte. Ltd. (WVE) on Tuesday reported a loss of $61.8 million in its third quarter. On a per-share basis, the Singapore-based company said it had a loss of 47 cents. |